Gina Wentling   Posted in News    Jan 18th, 2018

NeuroPointDX Announces Validation of First-Generation Autism Diagnostic Panel

NeuroPointDX, the neurodevelopmental disorders division of Stemina Biomarker Discovery, has validated 12 metabolic subtypes of autism spectrum disorder. The diagnostic blood test for ASD will be available later this year.

CEO Elizabeth Donley says, “This is a historic moment, not just for Stemina and NeuroPointDX, but for our knowledge and understanding of autism.”

Read the full press release.